Scientific Programme

Similar documents
08:45-08:55 Welcome Remarks and Programme Outline Scientific Co-Chairs

AIDS SOCIETY OF INDIA th th

versus CD4. PoC - Messaging - Specificity and - Ethics sensitivity of HIV - Feedback from diagnostic tests demonstration projects

ViiV Healthcare s Position on Prevention in HIV

Facing the Reality of Multidrug-Resistant Tuberculosis: Challenges and Potential Solutions in India

Program to control HIV/AIDS

Treat All : From Policy to Action - What will it take?

A PROFILE OF PATIENTS REGISTERED AT ART CENTRE AT SURAT MUNICIPAL INSTITUTE OF MEDICAL EDUCATION & RESEARCH IN SURAT CITY, GUJARAT, INDIA

CMC VELLORE ANNUAL RHEUMATOLOGY UPDATE Organized by: Department of Clinical Immunology and Rheumatology. 12 May 2017

( ISNR 2009) PROGRAMME. ( Incorporating Ramachandra Advanced Interventional Neuroradiology (RAIN- 2009)

HIV Epidemic in India

Management of Antiretroviral Treatment (ART) and Long-Term Adherence to ART

Session 1B - Auditorium Adult cases - Adherence - Mental health - STIs - Opportunistic Infections - TB - Drug Interactions Panel discussion

World Health Organization. A Sustainable Health Sector

rd th 3-4 December 2016, ITC Grand Chola, Chennai, India SCIENTIFIC PROGRAM

PROJECT ŚVETANA (Dawn) Elimination of new HIV infections among children by Scaling up PPTCT services in private health sector

Introduction: WHO recommends that criteria for starting ART be defined in national protocols and that these

Integration of services for HIV/AIDS and sexual and reproductive health

Tuberculosis-HIV epidemic situation and emerging challenges in North India

73rd NATCON Scientific Programme Day-1 (January 05,2019) Registration (08.00AM AM)

The new German strategy on HIV, Hepatitis B, C and STI, an integrated approach. Ines Perea Ministry of Health, Germany

ViiV Healthcare s Position on Continuous Innovation in Prevention, Testing, Treatment & Care of HIV

INCOFYRA 2018: Integrative Oncology: Future of Cancer Care Scientific Program: January 6, 2018, Saturday, Forenoon

Delivering Integrated HIV/TB Services in India: Challenges and Opportunities in National AIDS Control Program (NACP) IV.

Lessons learned and emerging challenges in Global Oral Health

3 rd EACS Standard of care for HIV and co-infections, Bucharest, 2019

HIV Situation in South-East Asia. HIV unit Department of Communicable Diseases

Prevention of Mother to Child Transmission of HIV: Our Experience in South India

South Africa s National HIV Programme. Dr Zuki Pinini HIV and AIDS and STIs Cluster NDOH. 23 October 2018

Overview of the TB epidemic globally and in India

SEHAT-The Health Initiative

Role of RNTCP in the management MDR-TB

ANNUAL MEETING OF INDIAN SOCIETY OF NEPHROLOGY SOUTHERN CHAPTER CONFERENCE CALICUT. Date: to Scientific Programme

Department Of AIDS Control (DAC) Ministry of Health and Family Welfare, GOI Chandralok Building, 36 - Janpath, New Delhi

Secretariat: IPMRD-IPL, A/405, Sangam, S.V. Road, Opp. Surya Hospital, Abv Kotak Mahindra Bank, Santacruz (West), Mumbai Web:

Treatment as Prevention in India: What will it take?

Agenda. KIGALI Serena Hotel, 7 th 8 th June, 2018

No adolescent living with HIV left behind: a coalition for action

Seroprevalance of HIV, HBV, HCV and Syphilis among High Risk Group and General Population at Kims, Amalapuram, India

Approach To Collagen vascular Dr. G.Narsimulu Disorders with Case Scenarios. Newer Oral Anti diabetic Drugs Dr. Sanjay Reddy.

NYS PrEP Programming. Lyn Stevens, NP, MS, ACRN Office of the Medical Director, AIDS Institute PrEP Monitoring in NYC and NYS February 19, 2016

Government of Canada Federal AIDS Initiative Milestones

Vatsalyam. National Conference on Mother and Child Health Care through Ayurveda

Page 1. Outline. Outline. Building specialized knowledge: HIV. Biological interactions. Social aspects of the epidemic. Programmatic actions

HIV Prevention, Care and Treatment Services in Prisons of North-Eastern States of India

Type 1 diabetes. Diabetes in Children-A poor cousin of type 2 diabetes. Incidence. Diabetes Nepal Conference

Scientific Programme 72 ND National Conference on Tuberculosis & Chest Diseases (NATCON 2017) DAY 1: AM to 5.10 PM

live DEC 2014 YENEPOYA UNIVERSITY, MANGALORE, INDIA. Join Radio ENT group on Facebook MediCon + IN ASSOCIATION WITH

IAS Conference Vienna 18 th to 23 rd July 2010 overview. Paul Clift King s College Hospital/UK-CAB

Access to Healthcare for Women and Children. A Philips CSR Initiative. Sumathi/ Anoop 8/31/17 An overview

Module 2: Integration of HIV Rapid Testing in HIV Prevention and Treatment Programs

Sex Work in Sub-Saharan Africa : Opportunities and Challenges

1997 to 2009 M.Sc Epidemiology Student project

Academic & Public Awareness Activities. Report February 2014 to February Nagpur Chapter

Guidance on Performance Evaluation of In-vitro Diagnostic Medical Devices

HIV in Zambia MINISTRY OF HEALTH. Dr Albert Mwango, BScHB, MBChB, MPH National Antiretroviral Program Coordinator,

transmission (MTCT) of

Population, Gender and Health in India

was found in Chennai in 1986, India has had an AIDS epidemic. 1 In many respects, however, its extent and complexities have only recently begun

WHO Global Health Sector Strategies HIV; Viral Hepatitis; Sexually Transmitted Infections

New Infections (all age groups)

PDF of Trial CTRI Website URL -

Scholars Research Library. Changing trends of HIV infection in children with relation to the ongoing PPTCT programme

Medical Challenges of HIV/AIDS pandemic: The WHO perspective. SOLTHIS HIV Forum

Colloque scientifique : L économie de la prévention Analysis of Cost-Effectiveness of HIV Prevention

INDIAN SOCIETY FOR CLINICAL RESEARCH 11th Annual ISCR Conference Collaborative Clinical Research for better Patient outcomes January, 2018

Translating Science to end HIV in Latin America and the Caribbean

INDIAN ORTHOPEDIC RHEUMATOLOGY ASSOCIATION SCIENFIC PROGRAMME. IORACON2017 Day th August 2017 Saturday 8.30am 9.

Immediate Offer of HIV Treatment: How To Deliver on the Second 90 (including Supply Chain Management and Drug Stockouts)

HIV/SRHR Integration for People Living with HIV

IMPACT AND OUTCOME INDICATORS IN THE NATIONAL HIV MONITORING AND EVALUATION FRAMEWORK

Facts & Figures. HIV Estimates

Global Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive

Botswana Advocacy paper on Resource Mobilisation for HIV and AIDS

To provide you with the basic concepts of HIV prevention using HIV rapid tests combined with counselling.

BLK Super Speciality Hospital

GLOBAL DRUG POLICY AND THE HIV/IDU EPIDEMIC IN EASTERN EUROPE AND CENTRAL ASIA. The critical need to scale up opioid substitution therapy

Using anti-hiv drugs for prevention

Dr. A. C. Dhariwal, Director, NCDC Directorate General of Health Services, 22, Sham Nath Marg, New Delhi

Positive Living among women infected with HIV.

REPORT. Organized by. Sponsored by

Date: November 28, 2010 Edition: Bangalore. The Times of India

DOWNLOAD OR READ : NATIONAL HIV AIDS STRATEGY PDF EBOOK EPUB MOBI

POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV

HIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare

WHO WHO AIDS 2018 JOIN US AT

Global health sector strategies on HIV, viral hepatitis and sexually transmitted infections ( )

Progress toward Universal ART Access: Innovations and Treatment 2.0. Marco Vitoria World Health Organization September 2013

Emma Zurowski PaSH Programme Lead BHA for Equality. Peter Bampton Sexual Health Lead LGBT Foundation. gmpash.org.uk.

STI and HIV Prevention and Care among Sex Workers

HIV Drug Resistance Surveillance and Monitoring in the Southeast Asia Region

South African Guidelines for the Safe Use of. Dr. Oscar Radebe

Predictors of ART adherence among HIV infected individuals in Dakar, Senegal

In collaboration with GLOBAL HEALTH SCIENCES, UNIVERSITY OF CALIFORNIA, SAN FRANCISCO. Training workshop

Analysis of Transfusion Transmitted Infections Among Blood Donors:To Prepare a Road Map for its Prevention and Control

SOCIETY FOR ETHNOPHARMACOLOGY 23/3 Saktigarh, Kolkata , India;

Place of addiction-informed comprehensive treatment in HIV care

Advancing Treatment 2.0: Progress on the 2013 Consolidated Guidelines What s new

Overview of 2013 WHO consolidated ARV guidelines and update plans. Marco Vitoria HIV/AIDS Department WHO Geneva September 2014

Prof D Prabhakaran, Vice President-Research PHFI

Transcription:

11th National Conference of AIDS Society of India- ASICON 2018 Hotel ITC Gardenia, Bangalore : Nov 2-4, 2018 Academic Partners ASHA Foundation, Bangalore; CAPRISA-South Africa; Forum of Parliamentarians on AIDS; Gilead Sciences Inc.; Medical Council of India (MCI)*; National AIDS Control Organisation (NACO); Peoples Health Organisation-India (PHO); UNAIDS Breaking Barriers for Health, Hope and Healing Day 1: Nov 2, 2018: 09 09:00-09:20 Welcome Remarks and Scientific Programme Outline Scientific Programme Scientific Dr. Jyoti Dhar, UK Dr. N Kumarasamy, Chennai 09:20-10:05 Oral Abstract Session I (1-4) Dr. Jyoti Dhar, UK Dr. Shirley James, Bangalore Session I 10:05-11:05 1. Elevated Alkaline Phosphatase in Patients with HIV: A spark in the dark? 2. Study of Sero-Positivity Of HBsAg & Anti-HCV Antibody In HIV Positive Individuals 3. Leveraging surveillance and community-driven case detection methods among the Key Population 4. India moving online: Its implications to HIV intervention program for Key Population HIV Epidemic Dr. Avik Medda, Kolkata Dr. K.K.Sharathchandra, Kalaburagi Dr. M.R.Parthasarathy, New Delhi Dr. P. Shah, New Delhi Dr. Herve Fleury, France Dr. Naval Chandra, Hyderabad 10:05-10:20 Global Epidemiology of HIV Dr. Mukta Sharma, WHO 10:20-10:40 NACO response to Indian HIV epidemic Dr. R S Gupta, NACO 10:40-10:55 Success and Challenges from Private sector Dr. Ishwar Gilada, Mumbai 11:05-11:20 Tea Break Session II 11:20-12:10 Diagnosis and Monitoring Dr. David Katzenstein, USA, Dr.V Chandrasekhar,Warangal 11:20-11:40 Implications of new international monitoring Dr. Vanita Gupta, Chandigarh SACS guidelines on National Program 11:40-12:00 Point of care assays for HIV: Where do we stand? Dr. Preeti Mehta, Mumbai

12:10-13:00 Inaugural ceremony & Felicitations Life-time Achievement Awards: Dr. Narendra Singh Potsangbam, Imphal Dr S Sacchidanand, Vice-Chancellor, Rajiv Gandhi University of Health Sciences & Director of Medical Education, Govt. of Karnataka 13:00-14:00 Lunch 14:00-14:35 Oral Abstracts Session- II (5-7) Dr. N Kumarasamy, Chennai Dr. K Gopalakrishnan, Calicut 5. Pitfalls in the Roadmap to Elimination of Mother To Child Transmission (EMTCT) of HIV in India 6. New solutions and old problems: Test and Treat Policy in South Gujarat 7. Enhanced Adherence Counseling in Mumbai ART: Scale up of a pilot project from an ART center Dr. U.C.Samudyatha, Surat Dr. Manvendra Singh Rathore, Surat Dr. Shrikala Acharya, Mumbai Session III 14:35-15:00 Plenary 1: Dr. Suniti Solomon Oration Newer approaches for HIV Prevention Dr. Sunil Solomon, Chennai Dr. G D Ravindran, Bangalore Dr. Nirupama Sista, USA Session IV 15:00-16:15 90-90-90: Challenges in the first 90 Dr. George Oommen, Mumbai Dr. S Murugan, Tirunelveli 15:00-15:20 Test and Treat: Where are we with testing? Dr. R.S.Gupta, NACO 15:20-15:40 Testing strategies in hidden and key populations Dr. Sunil Solomon, Chennai 15:40-16:00 Challenges in linkage to care Dr. B B Rewari, WHO 16:15-16:30 Tea Break Session V 16:30-17:05 Debate: How to identify people living with HIV- Should we test all citizens? How often? For Dr. Harsh Toshniwal, Ahmedabad Dr. VHT Swamy, Mysore Moderators: Dr. B.B.Rewari, WHO Dr. Alex Thomas, Bangalore Against Dr. Prakash Bora, Mumbai Dr. Ketan Ranpariya, Surat Session VI 17:05-18:15 Prevention Strategies -An Update Dr. Glory Alexander, Bangalore Dr. Satish Rao, Mangalore 17.05-17:25 Emerging Sexually Transmitted Infections (STIs) Dr. Jyoti Dhar, UK 17:25-17:45 PrEP Demonstration Programmes in India Dr. Nomita Chandhiok, ICMR 17:45-18:05 Preventing stigma: Role of Law Dr. B C Gupta, New Delhi 19:00-20:00: ASI Annual General Body Meeting

Day 2: Nov 3, 2018: 09:00-09:40 Oral Abstract Presentations III (8-10) Dr. Basavaraj Sajjan, Hubli Session VII 09:40-11:15 8. Vitality of Antiretroviral Compliance: Cryptococcal Meningitis Survival Analysis 9. Level of Awareness about Universal Precautions and PEP for HIV among Interns HIV and Co-infections Dr. S.D. Tilekar, Panchgani Dr. Prashant Mathapati, Salem Dr. P Narendra Singh, Imphal 09:40-10:00 Update on HPV management Dr. Joel Palefsky, USA 10:00-10:20 What is new in HCV? Dr. Juergen Rockstroh, Germany 10:20-10:40 Update on HBV therapy Dr. Ed Wilkins/Dr.Jyoti Dhar, UK 10:40-11:00 What is new in POC for co-infections? Dr. David Katzenstein,USA 11:15-11:30 Tea Break Session VIII 11:30-13:00 State of ART Dr. Franco Buonaguro, Italy, Dr. Ramesh Bhat,IADVL,Mangalore 11:30-11:50 What is new in initiating ART? 11:50-12:10 Pattern of resistance to PIs and Integrase inhibitors Dr. Rami Kantor, USA 12:10-12:30 Current 2 nd Line and 3 rd Line ART regimens Dr. N Kumarasamy, Chennai 12:30-12:50 Cure of HIV Dr. Herve Fleury, France 13:00-14:00 Lunch Session IX 14:00-15:30 Session X 15:30-16:00 Interactive clinical case discussions Case Presentations Dr. Hiten Thaker, UK (Patient readiness) Dr. S K Guha, Kolkata (Resistance) Dr. R Sajithkumar, Kottayam(Toxicities) Dr. G Manoharan, Coimbatore(Mitochondrial Myopathy) Dr. Raj Harjani, Mumbai (Malignancy) Dr. Rajeev Mehta, Mumbai (Radiology) Plenary 2: Dr. Mark Wainberg Oration Newer targets & ARVs in pipeline Panelists: Dr. Nalin Nag, Delhi Dr. Murugesh Pastapur, Gulbarga Dr. Salil Bendre, Mumbai Dr. Ishwar Gilada, Mumbai Dr. Juergen Rockstroh, Germany 16:00-16:15 Tea-Break

Session XI 16:15-17:30 ARVs for special populations Dr. Ruby Bansal, Ghaziabad 16.15-16.35 ARVs for maintenance and long acting ARVs 16:35-16:50 ART in Children and Adolescent Dr. S N Mothi, Mysore 16:50-17:05 What is new in ART for Women? Dr. S. Poongulali, Chennai 17:05-17:20 HIV and Aging Dr. P Narendra Singh, Imphal Session XII 17:30-19:00 ARV toxicities Dr. Rami Kantor, USA Dr. Sumantoke Bagchi, Mumbai 17:30-17:50 Renal toxicities - Do we need TAF in India? Dr. Atul Patel, Ahmedabad 17:50-18:05 Chaos with EFV- Is there a role for Rilpivirine? 18:05-18:25 Long-term PI toxicities- What to do? Dr. Sanjay Pujari, Pune 18:25-18:45 Common drug interactions with ARVs Dr. Hiten Thaker, UK

Day 3: Nov 4, 2018: Session XIII 08:30-10:00 HIV and Non-communicable diseases Dr. Ravi Shankar, Bangalore Dr. M Satyanarayanan, Hyderabad 08:30-08:45 HIV and Cardiac Dr. Alok Shetty, Bangalore 08:45-09:00 HIV and kidney Dr. Priyanka P, Bangalore 09:00-09:15 HIV & Neurocognitive disorders Dr. Ameet Dravid, Pune 09:15-09:30 HIV & Metabolic complications Dr. Trupti Gilada, Mumbai 09:30-09:50 HIV and non AIDS Malignancies Dr. Franco Buonaguro, Italy Session XIV 10:00-10:25 Plenary III: Dr. K C Mohanty Oration TB HIV Integration: Overview Dr. G D Ravindran, Bangalore Dr. Kogie Naidoo, South Africa 10:25-10:40 Tea Break Session XV 10:40-11:45 TB-HIV Co-enemies Dr. Srikanth Tripathy, Chennai Dr. Milind Bhrushundi, Nagpur 10:40-11:00 TBD TBD 11:00-11:15 Epidemiology of MDR TB in India Dr. Sanjay Kumar Matto, RNTCP 11:15-11:30 Newer drugs for Treatment and Prevention Dr. K Satish, Bangalore Session XVI 11:45-13.00 Emerging issues in HIV in India Dr. Shashi Sangle, Pune 11:45-12:00 Sustainability of Public ARV program in India Dr. R R Gangakedhkar, Pune 12:00-12:15 How to motivate the young doctors into HIV care? Dr. Jyoti Dhar, UK 12:15-12:30 Public-Private Partnership: What can NACO/ASI Do? Dr. Glory Alexander, Bangalore 12:30-12:45 NACO and RNTCP Perspective on PPP NACO/ RNTCP 13:00-13:45 Valedictory function 13:45 onwards Lunch